DrugPatentWatch Database Preview
RITUXAN HYCELA Drug Profile
» See Plans and Pricing
Summary for Tradename: RITUXAN HYCELA
| Patents: | 739 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for RITUXAN HYCELA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RITUXAN HYCELA |
Recent Clinical Trials for RITUXAN HYCELA
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 3 |
| Academic and Community Cancer Research United | Phase 2 |
| National Cancer Institute (NCI) | Phase 2 |
Recent Litigation for RITUXAN HYCELA
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| ABBVIE INC. v. DR. REDDY'S LABORATORIES, INC. | 2020-07-22 |
| Genentech, Inc. v. Samsung Bioepis Co. Ltd. | 2020-06-28 |
| Pharmacyclics LLC v. Alvogen Pine Brook, LLC | 2020-03-20 |
See all RITUXAN HYCELA litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| Celltrion, Inc. | 2018-05-04 |
| Apotex Inc. | 2018-02-23 |
| Forty Seven, Inc. | 2018-01-08 |
Patent Text Search: US Patents for RITUXAN HYCELA
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Pharmacyclics LLC (Sunnyvale, CA) | 2030-06-03 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Array BioPharma Inc. (Boulder, CO) | 2028-10-22 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for RITUXAN HYCELA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2686020 | Start Trial |
| Russian Federation | 2018131134 | Start Trial |
| Japan | 2008545958 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for RITUXAN HYCELA
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2017C/054 | Belgium | Start Trial | PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627 |
| LUC00044 | Luxembourg | Start Trial | PRODUCT NAME: INOTUZUMAB OZOGAMICINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BESPONSA ); AUTHORISATION NUMBER AND DATE: EU/1/17/1200 20170703 |
| CA 2017 00053 | Denmark | Start Trial | PRODUCT NAME: ANTISTOF-LAEGEMIDDEL-KONJUGAT, HVORI ET CD22-RETTET ANTISTOF ER BUNDET TIL N-ACETYL-GAMMA-CALICHEAMICIN, SVARENDE TIL INOTUZUMAB OZOGAMICIN; REG. NO/DATE: EU/1/17/1200 20170703 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
